Open AccessTPMT Genetic Variability and Its Association with Hematotoxicity in Indonesian Children with Acute Lymphoblastic Leukemia in Maintenance Therapy
Author(s) -
Dewi Selvina Rosdiana,
Rianto Setiabudy,
Rizka Andalusia,
Djajadiman Gatot,
Melva Louisa,
Saptawati Bardosono,
Instiaty Instiaty
Publication year - 2021
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s288988
Subject(s) - thiopurine methyltransferase , medicine , mercaptopurine , maintenance therapy , discontinuation , neutropenia , azathioprine , pediatrics , toxicity , chemotherapy , disease
Hematotoxicity monitoring in children with acute lymphoblastic leukemia (ALL) is critical to preventing life-threatening infections and drug discontinuation. The primary drug that causes hematotoxicity in ALL children is 6-mercaptopurine (6-MP). Genetic variability of the drug-metabolizing enzymes of 6-MP, thiopurine S -methyltransferase ( TPMT ), is one factor that might increase the susceptibility of children to hematotoxicity. The present study aimed to determine the variability in TPMT genotypes and phenotypes and its association with the occurrence of hematotoxicity in ALL children in maintenance therapy.